Summary of response rates—all-treated population
| mCRPC (n=24) | NSCLC (n=20) | |
| Best overall response, n (%) | ||
| CR* | 0 | 0 |
| PR* | 1 (4.2) | 0 |
| Stable disease | 5 (20.8) | 13 (65.0) |
| Non-CR/non-PD† | 9 (37.5) | 0 |
| PD | 5 (20.8) | 5 (25.0) |
| Not evaluable‡ | 4 (16.7) | 2 (10.0) |
| Unconfirmed CR | 0 | 0 |
| Unconfirmed PR | 1 (4.2) | 0 |
| PSA response, n (%) | ||
| Responders* | 1 (4.2) | – |
| Unconfirmed response | 1 (4.2) | – |
| Overall response, n (%) | ||
| Responders (CR, PR, or PSA responders)* | 1 (4.2) | 0 |
| 90% CI§ | 0.2 to 18.3 | 0.0 to 13.9 |
*Confirmation of response is required.
†Including patients with no target and non-target lesions identified at baseline and no new lesions reported in postbaseline tumor assessments, or patients with only non-target lesions identified at baseline with non-CR/non-PD reported for non-target lesion and no new lesions reported in postbaseline tumor assessments.
‡Including patients with no postbaseline evaluation prior to the initiation of a new anticancer therapy or the data cut-off date.
§Estimated using Clopper-Pearson method.
CR, complete response; mCRPC, metastatic castration-resistant prostate cancer; NSCLC, non-small cell lung cancer; PD, progressive disease; PR, partial response; PSA, prostate-specific antigen.;